Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) Interest & Investment Income (2016 - 2017)

Syndax Pharmaceuticals (SNDX) has disclosed Interest & Investment Income for 3 consecutive years, with $462000.0 as the latest value for Q4 2017.

  • For Q4 2017, Interest & Investment Income rose 72.39% year-over-year to $462000.0; the TTM value through Dec 2017 reached $1.4 million, up 48.74%, while the annual FY2025 figure was $22.7 million, 12.88% down from the prior year.
  • Interest & Investment Income hit $462000.0 in Q4 2017 for Syndax Pharmaceuticals, up from $411000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $462000.0 in Q4 2017 and bottomed at -$524000.0 in Q4 2015.
  • Average Interest & Investment Income over 3 years is $80333.3, with a median of $263500.0 recorded in 2016.
  • Year-over-year, Interest & Investment Income soared 217.03% in 2016 and then rose 5.07% in 2017.
  • Syndax Pharmaceuticals' Interest & Investment Income stood at -$524000.0 in 2015, then surged by 151.15% to $268000.0 in 2016, then surged by 72.39% to $462000.0 in 2017.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $462000.0, $411000.0, and $290000.0 for Q4 2017, Q3 2017, and Q2 2017 respectively.